A randomized, double-blind, phase III study in India for comparing efficacy, safety, and PK of ZRC-3277 (pertuzumab biosimilar) with Perjeta® in patients with HER2-positive metastatic breast cancer
Article in Clinical Breast Cancer (July 2024)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
Article in Clinical Breast Cancer (July 2024)
Article in iScience (May 2024)
Article in BMC Cancer (December 2022)